Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00YSJ
|
||||
| Former ID |
DCL000313
|
||||
| Drug Name |
Tecadenoson
|
||||
| Synonyms |
CVT-510; Tecadenoson (USAN/INN); N-(3-Tetrahydrofuranyl)-6-aminopurine riboside; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Atrial fibrillation; Cardiac arrhythmias [ICD9: 272, 427.31, 427; ICD10:E78, I48, I47-I49] | Discontinued in Phase 3 | [1], [2] | ||
| Company |
CV Therapeutics
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H19N5O5
|
||||
| InChI |
InChI=1S/C14H19N5O5/c20-3-8-10(21)11(22)14(24-8)19-6-17-9-12(15-5-16-13(9)19)18-7-1-2-23-4-7/h5-8,10-11,14,20-22H,1-4H2,(H,15,16,18)/t7-,8-,10-,11-,14-/m1/s1
|
||||
| InChIKey |
OESBDSFYJMDRJY-BAYCTPFLSA-N
|
||||
| CAS Number |
CAS 204512-90-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Agonist | [3], [4] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5592). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010504) | ||||
| REF 3 | Adenosine receptors and cardiovascular disease: the adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc Toxicol. 2003;3(1):71-88. | ||||
| REF 4 | CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.